{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T19:04:37Z","timestamp":1775934277482,"version":"3.50.1"},"reference-count":217,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cla Caixa\u201d Foundation","award":["100010434"],"award-info":[{"award-number":["100010434"]}]},{"name":"\u201cla Caixa\u201d Foundation","award":["LCF\/PR\/HP21\/52310015"],"award-info":[{"award-number":["LCF\/PR\/HP21\/52310015"]}]},{"name":"\u201cla Caixa\u201d Foundation","award":["2021.00895.CEECIND"],"award-info":[{"award-number":["2021.00895.CEECIND"]}]},{"name":"\u201cla Caixa\u201d Foundation","award":["UI\/BD\/154738\/2023"],"award-info":[{"award-number":["UI\/BD\/154738\/2023"]}]},{"name":"FCT, I.P","award":["100010434"],"award-info":[{"award-number":["100010434"]}]},{"name":"FCT, I.P","award":["LCF\/PR\/HP21\/52310015"],"award-info":[{"award-number":["LCF\/PR\/HP21\/52310015"]}]},{"name":"FCT, I.P","award":["2021.00895.CEECIND"],"award-info":[{"award-number":["2021.00895.CEECIND"]}]},{"name":"FCT, I.P","award":["UI\/BD\/154738\/2023"],"award-info":[{"award-number":["UI\/BD\/154738\/2023"]}]},{"DOI":"10.13039\/501100001871","name":"\u201cFunda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\u201d","doi-asserted-by":"publisher","award":["100010434"],"award-info":[{"award-number":["100010434"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"\u201cFunda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\u201d","doi-asserted-by":"publisher","award":["LCF\/PR\/HP21\/52310015"],"award-info":[{"award-number":["LCF\/PR\/HP21\/52310015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"\u201cFunda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\u201d","doi-asserted-by":"publisher","award":["2021.00895.CEECIND"],"award-info":[{"award-number":["2021.00895.CEECIND"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"\u201cFunda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia\u201d","doi-asserted-by":"publisher","award":["UI\/BD\/154738\/2023"],"award-info":[{"award-number":["UI\/BD\/154738\/2023"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Protein\u2013protein interactions (PPIs) form an intricate cellular network known as the interactome, which is essential for various cellular processes, such as gene regulation, signal transduction, and metabolic pathways. The dysregulation of this network has been closely linked to various disease states. In cancer, these aberrant PPIs, termed oncogenic PPIs (OncoPPIs), are involved in tumour formation and proliferation. Therefore, the inhibition of OncoPPIs becomes a strategy for targeted cancer therapy. Small molecule inhibitors have been the dominant strategy for PPI inhibition owing to their small size and ability to cross cell membranes. However, peptide-based inhibitors have emerged as compelling alternatives, offering distinct advantages over small molecule inhibitors. Peptides, with their larger size and flexible backbones, can effectively engage with the broad interfaces of PPIs. Their high specificity, lower toxicity, and ease of modification make them promising candidates for targeted cancer therapy. Over the past decade, significant advancements have been made in developing peptide-based inhibitors. This review discusses the critical aspects of targeting PPIs, emphasizes the significance of OncoPPIs in cancer therapy, and explores the advantages of using peptide-based inhibitors as therapeutic agents. It also highlights recent progress in peptide design aimed at overcoming the limitations of peptide therapeutics, offering a comprehensive overview of the current landscape and potential of peptide-based inhibitors in cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms26073117","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:36:48Z","timestamp":1743136608000},"page":"3117","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Potential of Peptide-Based Inhibitors in Disrupting Protein\u2013Protein Interactions for Targeted Cancer Therapy"],"prefix":"10.3390","volume":"26","author":[{"given":"Alexandra L.","family":"Afonso","sequence":"first","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"given":"Catarina T.","family":"Cavaleiro","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-7562","authenticated-orcid":false,"given":"Miguel A. R. B.","family":"Castanho","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2989-7208","authenticated-orcid":false,"given":"Vera","family":"Neves","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-9038","authenticated-orcid":false,"given":"Marco","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"},{"name":"Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"ref_1","unstructured":"OECD (2024, May 07). OECD Indicators: Health at a Glance 2023. Available online: https:\/\/www.oecd-ilibrary.org\/social-issues-migration-health\/health-at-a-glance-2023_7a7afb35-en."},{"key":"ref_2","unstructured":"Cancer IAfRo (2024, May 07). IARC Biennial Report 2022\u20132023. Available online: https:\/\/www.iarc.who.int\/news-events\/iarc-biennial-report-2022-2023\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S1470-2045(21)00639-2","article-title":"Toxicity and efficacy of chronomodulated chemotherapy: A systematic review","volume":"23","author":"Printezi","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"123056","DOI":"10.1016\/j.ijpharm.2023.123056","article-title":"Ibrutinib amorphous solid dispersions with enhanced dissolution at colonic pH for the localized treatment of colorectal cancer","volume":"641","author":"Patel","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.46747\/cfp.6807515","article-title":"Targeted cancer therapies: Clinical pearls for primary care","volume":"68","author":"Shuel","year":"2022","journal-title":"Can. Fam. Physician"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Victoir, B., Croix, C., and Gouilleux, F. (2024). Targeted Therapeutic Strategies for the Treatment of Cancer. Cancers, 16.","DOI":"10.3390\/cancers16020461"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"216633","DOI":"10.1016\/j.canlet.2024.216633","article-title":"Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma","volume":"586","author":"Zhang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1611715","DOI":"10.3389\/pore.2024.1611715","article-title":"Targeted therapeutic options in early and metastatic NSCLC-overview","volume":"30","author":"Korompay","year":"2024","journal-title":"Pathol. Oncol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Guo, M., Sun, Y., and Wei, Y. (2024). Advances in targeted therapy and biomarker research in thyroid cancer. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1372553"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Marqus, S., Pirogova, E., and Piva, T.J. (2017). Evaluation of the use of therapeutic peptides for cancer treatment. J. Biomed. Sci., 24.","DOI":"10.1186\/s12929-017-0328-x"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vecchio, I., Tornali, C., and Bragazzi, N.L. (2018). The Discovery of Insulin: An Important Milestone in the History of Medicine. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00613"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rossino, G., Marchese, E., Galli, G., Verde, F., Finizio, M., Serra, M., Linciano, P., and Collina, S. (2023). Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era. Molecules, 28.","DOI":"10.3390\/molecules28207165"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2165\/00003495-200565120-00008","article-title":"Exenatide","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","article-title":"Pramlintide in the treatment of type 1 and type 2 diabetes mellitus","volume":"27","author":"Ryan","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: A novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2007.03067.x","article-title":"A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly","volume":"68","author":"Andries","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jaci.2007.12.411","article-title":"Icatibant, a Selective Bradykinin B2 Receptor Antagonist, Proves Effective and Safe in Treating the Symptoms of Hereditary Angioedema (HAE) Attacks","volume":"121","author":"Riedl","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/TCRM.S5688","article-title":"Review of mifamurtide in the treatment of patients with osteosarcoma","volume":"6","author":"Kager","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: A novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","article-title":"Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data","volume":"95","author":"Falutz","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"Food and Drug Administration approval: Carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dot.2013.49.9.2020940","article-title":"Lixisenatide for the treatment of type 2 diabetes","volume":"49","author":"Petersen","year":"2013","journal-title":"Drugs Today"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for Erythropoietic Protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection","volume":"370","author":"Wilcox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r\u2013Ombitasvir and Dasabuvir with Ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: First Global Approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs. Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40265-017-0718-0","article-title":"Plecanatide: First Global Approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the Treatment of Vasodilatory Shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: Single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Argente","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100512","DOI":"10.1016\/j.xkme.2022.100512","article-title":"Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies","volume":"4","author":"Topf","year":"2022","journal-title":"Kidney Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40265-021-01594-y","article-title":"Odevixibat: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet. Med."},{"key":"ref_50","first-page":"680","article-title":"The effectiveness and value of tirzepatide for type 2 diabetes mellitus","volume":"28","author":"Nikitin","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: A randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","article-title":"Motixafortide: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.15585\/mmwr.mm7251a1","article-title":"SARS-CoV-2 Rebound with and without Use of COVID-19 Oral Antivirals","volume":"72","author":"Smith","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40265-024-02019-2","article-title":"Correction: Zilucoplan: First Approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40265-024-02023-6","article-title":"Danicopan: First Approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Thanasomboon, R., Kalapanulak, S., and Netrphan, S. (2020). Exploring dynamic protein-protein interactions in cassava through the integrative interactome network. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-63536-0"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mas.21574","article-title":"Discovering cellular protein-protein interactions: Technological strategies and opportunities","volume":"38","author":"Titeca","year":"2019","journal-title":"Mass Spectrom. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/gm441","article-title":"Protein-protein interaction networks: Probing disease mechanisms using model systems","volume":"5","author":"Kuzmanov","year":"2013","journal-title":"Genome Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41588-020-00774-y","article-title":"Comprehensive characterization of protein\u2013protein interactions perturbed by disease mutations","volume":"53","author":"Cheng","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.sbi.2005.06.001","article-title":"Protein-protein interactions in human disease","volume":"15","author":"Ryanm","year":"2005","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/156802611794072614","article-title":"Protein-protein interactions and cancer: Targeting the central dogma","volume":"11","author":"Garner","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"14356","DOI":"10.1038\/ncomms14356","article-title":"The OncoPPi network of cancer-focused protein\u2013protein interactions to inform biological insights and therapeutic strategies","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-020-00850-0","article-title":"The design and development of covalent protein-protein interaction inhibitors for cancer treatment","volume":"13","author":"Cheng","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kar, G., Gursoy, A., and Keskin, O. (2009). Human cancer protein-protein interaction network: A structural perspective. PLoS Comput. Biol., 5.","DOI":"10.1371\/journal.pcbi.1000601"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, X., Ni, D., and Liu, Y. (2021). Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions. Front. Chem., 9.","DOI":"10.3389\/fchem.2021.682675"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1038\/s41467-023-39909-0","article-title":"Discovering functionally important sites in proteins","volume":"14","author":"Cagiada","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/bies.201300066","article-title":"What is the total number of protein molecules per cell volume? A call to rethink some published values","volume":"35","author":"Milo","year":"2013","journal-title":"Bioessays"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12551-019-00570-x","article-title":"Protein-protein interaction modulators: Advances, successes and remaining challenges","volume":"11","author":"Mabonga","year":"2019","journal-title":"Biophys. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cbpa.2019.02.012","article-title":"Modulating protein-protein interaction networks in protein homeostasis","volume":"50","author":"Zhong","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: Drug discovery faces the protein\u2013protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41586-020-2188-x","article-title":"A reference map of the human binary protein interactome","volume":"580","author":"Luck","year":"2020","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","article-title":"Recent advances in the development of protein\u2013protein interactions modulators: Mechanisms and clinical trials","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41594-022-00910-8","article-title":"Towards a structurally resolved human protein interaction network","volume":"30","author":"Burke","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Devkota, P., and Wuchty, S. (2020). Controllability analysis of molecular pathways points to proteins that control the entire interaction network. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59717-6"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1021\/cr400698c","article-title":"Modulators of Protein\u2013Protein Interactions","volume":"114","author":"Milroy","year":"2014","journal-title":"Chem. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.drudis.2013.10.027","article-title":"Modelling three-dimensional protein structures for applications in drug design","volume":"19","author":"Schmidt","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","article-title":"Protein structure-based drug design: From docking to molecular dynamics","volume":"48","author":"Caflisch","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein\u2013protein interactions: Progressing towards the dream","volume":"3","author":"Arkin","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2012.10","article-title":"Features of protein\u2013protein interactions that translate into potent inhibitors: Topology, surface area and affinity","volume":"14","author":"Smith","year":"2012","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/iub.383","article-title":"Small-molecule protein-protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations","volume":"62","author":"Buchwald","year":"2010","journal-title":"IUBMB Life"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cmdc.200600004","article-title":"Drugs Targeting Protein\u2013Protein Interactions","volume":"1","year":"2006","journal-title":"ChemMedChem"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/med.21585","article-title":"Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery","volume":"39","author":"Ni","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1006\/jmbi.1998.2439","article-title":"The atomic structure of protein-protein recognition sites","volume":"285","author":"Conte","year":"1999","journal-title":"J. Mol. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cbpa.2018.06.004","article-title":"Inhibitors of protein-protein interactions (PPIs): An analysis of scaffold choices and buried surface area","volume":"44","author":"Ran","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","article-title":"Targeting protein-protein interactions as an anticancer strategy","volume":"34","author":"Ivanov","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmbi.1998.1843","article-title":"Anatomy of hot spots in protein interfaces","volume":"280","author":"Bogan","year":"1998","journal-title":"J. Mol. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.str.2004.04.009","article-title":"Protein-Protein Interactions: Coupling of Structurally Conserved Residues and of Hot Spots across Interfaces. Implications for Docking","volume":"12","author":"Halperin","year":"2004","journal-title":"Structure"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.chembiol.2011.01.005","article-title":"Context-based identification of protein-protein interfaces and \u201chot-spot\u201d residues","volume":"18","author":"Geppert","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/prot.21396","article-title":"Hot spots\u2014A review of the protein-protein interface determinant amino-acid residues","volume":"68","author":"Moreira","year":"2007","journal-title":"Proteins"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/bioinformatics\/btx743","article-title":"The OncoPPi Portal: An integrative resource to explore and prioritize protein-protein interactions for cancer target discovery","volume":"34","author":"Ivanov","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cell.2015.06.043","article-title":"The BioPlex Network: A Systematic Exploration of the Human Interactome","volume":"162","author":"Huttlin","year":"2015","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cell.2015.11.037","article-title":"A Proteome-wide Fission Yeast Interactome Reveals Network Evolution Principles from Yeasts to Human","volume":"164","author":"Vo","year":"2016","journal-title":"Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.33954","article-title":"Mapping oncogenic protein interactions for precision medicine","volume":"151","author":"Francis","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/pro.3978","article-title":"The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions","volume":"30","author":"Oughtred","year":"2021","journal-title":"Protein Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.cell.2021.04.011","article-title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome","volume":"184","author":"Huttlin","year":"2021","journal-title":"Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"D841","DOI":"10.1093\/nar\/gkr1088","article-title":"The IntAct molecular interaction database in 2012","volume":"40","author":"Kerrien","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"D572","DOI":"10.1093\/nar\/gkl950","article-title":"MINT: The Molecular INTeraction database","volume":"35","author":"Ceol","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"D408","DOI":"10.1093\/nar\/gkw985","article-title":"HIPPIE v2.0: Enhancing meaningfulness and reliability of protein-protein interaction networks","volume":"45","author":"Schaefer","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"D1351","DOI":"10.1093\/nar\/gkaa1075","article-title":"PINA 3.0: Mining cancer interactome","volume":"49","author":"Du","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10826068.2019.1692217","article-title":"Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)\/PD-1 ligand 1 (PD-1\/PD-L1)","volume":"50","author":"Wen","year":"2019","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: From drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1200\/JCO.2013.49.8782","article-title":"Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: Is afatinib better or simply newer?","volume":"31","author":"Langer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: First Approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1087057114562544","article-title":"New horizons in therapeutic antibody discovery: Opportunities and challenges versus small-molecule therapeutics","volume":"20","author":"Smith","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.copbio.2015.04.006","article-title":"Alternative modulation of protein\u2013protein interactions by small molecules","volume":"35","author":"Fischer","year":"2015","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Poduval, P., Parsekar, S., and Meena, S.N. (2023). Chapter 10\u2014Small molecules vs. biologics. New Horizons in Natural Compound Research, Academic Press.","DOI":"10.1016\/B978-0-443-15232-0.00001-1"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: Current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.sbi.2016.12.009","article-title":"Peptides and peptidomimetics as regulators of protein-protein interactions","volume":"44","author":"Cunningham","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic Approaches to Optimizing Peptide ADME Properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cbpa.2013.10.011","article-title":"Druggable protein\u2013protein interactions\u2014From hot spots to hot segments","volume":"17","author":"London","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and Pharmacokinetic\u2013Pharmacodynamic Correlations of Therapeutic Peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bpc.2018.11.002","article-title":"Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis","volume":"244","author":"Chen","year":"2019","journal-title":"Biophys. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.drudis.2021.01.022","article-title":"Converting peptides into drugs targeting intracellular protein\u2013protein interactions","volume":"26","author":"Philippe","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41589-019-0245-2","article-title":"In-solution enrichment identifies peptide inhibitors of protein-protein interactions","volume":"15","author":"Touti","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: Challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1002\/anie.201916257","article-title":"Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions","volume":"59","author":"Ricardo","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/acs.jmedchem.7b00768","article-title":"Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models","volume":"61","author":"Yang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10098","DOI":"10.1021\/acs.jmedchem.9b00456","article-title":"Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide","volume":"62","author":"Dougherty","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1039\/D3SC05738K","article-title":"Biocompatible strategies for peptide macrocyclisation","volume":"15","author":"He","year":"2024","journal-title":"Chem. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1039\/D1SC00165E","article-title":"Peptide-based inhibitors of protein-protein interactions: Biophysical, structural and cellular consequences of introducing a constraint","volume":"12","author":"Wang","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/9780470559277.ch130202","article-title":"Synthesis of hydrogen-bond surrogate \u03b1-helices as inhibitors of protein-protein interactions","volume":"6","author":"Miller","year":"2014","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1021\/cb500271c","article-title":"Crystal structures of stapled and hydrogen bond surrogate peptides targeting a fully buried protein-helix interaction","volume":"9","author":"Douse","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"12252","DOI":"10.1021\/ja0466659","article-title":"A highly stable short alpha-helix constrained by a main-chain hydrogen-bond surrogate","volume":"126","author":"Chapman","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"FDD75","DOI":"10.4155\/fdd-2022-0005","article-title":"Overcoming the Shortcomings of Peptide-Based Therapeutics","volume":"4","author":"Lamers","year":"2022","journal-title":"Future Drug Discov."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2015.12.084","article-title":"Peptide-based inhibitors of protein-protein interactions","volume":"26","author":"Berlicki","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1002\/anie.200901059","article-title":"A single alpha-helical turn stabilized by replacement of an internal hydrogen bond with a covalent ethylene bridge","volume":"48","author":"Vernall","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1039\/C7OB02852K","article-title":"Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein \u03b1-turn","volume":"16","author":"Wang","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1039\/C1CC14730G","article-title":"Design, synthesis and protein-targeting properties of thioether-linked hydrogen bond surrogate helices","volume":"48","author":"Mahon","year":"2012","journal-title":"Chem. Commun."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e202204207","DOI":"10.1002\/slct.202204207","article-title":"Impact of Hydrogen-Bond Surrogate Model on Helix Stabilization and Development of Protein-Protein Interaction Inhibitors","volume":"8","author":"Pal","year":"2023","journal-title":"ChemistrySelect"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1002\/anie.200501603","article-title":"Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: Application to Bcl-xL","volume":"44","author":"Wang","year":"2005","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2-p53 interaction for cancer therapy: Are we there yet?","volume":"21","author":"Nag","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cbic.201000378","article-title":"High specificity in protein recognition by hydrogen-bond-surrogate \u03b1-helices: Selective inhibition of the p53\/MDM2 complex","volume":"11","author":"Henchey","year":"2010","journal-title":"Chembiochem"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Hillig, R.C., and Bader, B. (2022). Chapter Six\u2014Targeting RAS oncogenesis with SOS1 inhibitors. Advances in Cancer Research, Academic Press.","DOI":"10.1016\/bs.acr.2021.07.001"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nchembio.612","article-title":"An orthosteric inhibitor of the Ras-Sos interaction","volume":"7","author":"Patgiri","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.ddtec.2011.07.006","article-title":"\u03b2-Hairpin protein epitope mimetic technology in drug discovery","volume":"9","author":"Obrecht","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wen, J., Liao, H., and Stachowski, K. (2020). Rational design of cell-permeable cyclic peptides containing a d-Pro-l-Pro motif. Bioorg. Med. Chem., 28.","DOI":"10.1016\/j.bmc.2020.115711"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/anie.200353242","article-title":"Using a beta-hairpin to mimic an alpha-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction","volume":"43","author":"Fasan","year":"2004","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1039\/C7OB02952G","article-title":"Contiguous hydrophobic and charged surface patches in short helix-constrained peptides drive cell permeability","volume":"16","author":"Perry","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1021\/ol503310r","article-title":"Design of stable \u03b2-hairpin mimetics through backbone disulfide bonds","volume":"17","author":"Mali","year":"2015","journal-title":"Org. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1021\/acs.orglett.5b01017","article-title":"Trp-Trp Cross-Linking: A Structure\u2013Reactivity Relationship in the Formation and Design of Hyperstable Peptide \u03b2-Hairpin and \u03b1-Helix Scaffolds","volume":"17","author":"Makwana","year":"2015","journal-title":"Org. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/ar700259k","article-title":"\u03b2-Hairpin Peptidomimetics: Design, Structures and Biological Activities","volume":"41","author":"Robinson","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bbrc.2020.04.018","article-title":"Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1\/PD-L1 axis","volume":"527","author":"Wang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11623","DOI":"10.1021\/ja405108p","article-title":"In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide","volume":"135","author":"Ji","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1021\/acs.jcim.1c00029","article-title":"Solution-State Preorganization of Cyclic \u03b2-Hairpin Ligands Determines Binding Mechanism and Affinities for MDM2","volume":"61","author":"Ge","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1039\/C9OB00564A","article-title":"\u03b2-Hairpins as peptidomimetics of human phosphoprotein-binding domains","volume":"17","author":"Batalha","year":"2019","journal-title":"Org. Biomol. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1021\/jm4011675","article-title":"Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress","volume":"57","author":"Walensky","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1021\/acs.chemrev.0c00532","article-title":"Stapled Helical Peptides Bearing Different Anchoring Residues","volume":"120","author":"Li","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Guerlavais, V., and Sawyer, T.K. (2014). Chapter Twenty-One\u2014Advancements in Stapled Peptide Drug Discovery & Development. Annual Reports in Medicinal Chemistry, Academic Press.","DOI":"10.1016\/B978-0-12-800167-7.00021-3"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1039\/D1CB00087J","article-title":"Entropy of stapled peptide inhibitors in free state is the major contributor to the improvement of binding affinity with the GK domain","volume":"2","author":"Unarta","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/cbic.201200175","article-title":"Peptide bicycles that inhibit the Grb2 SH2 domain","volume":"13","author":"Quartararo","year":"2012","journal-title":"ChemBioChem"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nprot.2011.324","article-title":"Synthesis of all-hydrocarbon stapled \u03b1-helical peptides by ring-closing olefin metathesis","volume":"6","author":"Kim","year":"2011","journal-title":"Nat. Protoc."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1002\/anie.201602079","article-title":"Helix Nucleation by the Smallest Known \u03b1-Helix in Water","volume":"55","author":"Hoang","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1074-5521(02)00109-6","article-title":"Using an azobenzene cross-linker to either increase or decrease peptide helix content upon trans-to-cis photoisomerization","volume":"9","author":"Flint","year":"2002","journal-title":"Chem. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"17704","DOI":"10.1021\/ja307599z","article-title":"Development of \u03b1-Helical Calpain Probes by Mimicking a Natural Protein\u2013Protein Interaction","volume":"134","author":"Jo","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1021\/jo800142s","article-title":"Synthesis and Conformational Analysis of a Cyclic Peptide Obtained via i to i+4 Intramolecular Side-Chain to Side-Chain Azide\u2212Alkyne 1,3-Dipolar Cycloaddition","volume":"73","author":"Cantel","year":"2008","journal-title":"J. Org. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e202203624","DOI":"10.1002\/chem.202203624","article-title":"Fine Tuning the Properties of Stapled Peptides by Stereogenic \u03b1-Amino Acid Bridges","volume":"29","author":"Wang","year":"2023","journal-title":"Chemistry"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccr.2010.10.024","article-title":"A stapled p53 helix overcomes HDMX-mediated suppression of p53","volume":"18","author":"Bernal","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"107137","DOI":"10.1016\/j.phrs.2024.107137","article-title":"Therapeutic stapled peptides: Efficacy and molecular targets","volume":"203","author":"Li","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1039\/C8SC03275K","article-title":"Dithiocarbamate-inspired side chain stapling chemistry for peptide drug design","volume":"10","author":"Li","year":"2019","journal-title":"Chem. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.7150\/thno.75444","article-title":"Design of stapled peptide-based PROTACs for MDM2\/MDMX atypical degradation and tumor suppression","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Chen, B., Li, Y., and Bai, H. (2023). Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment. Bioorg. Chem., 140.","DOI":"10.1016\/j.bioorg.2023.106770"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1002\/anie.201503975","article-title":"A Thiol-Ene Coupling Approach to Native Peptide Stapling and Macrocyclization","volume":"54","author":"Wang","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"16374","DOI":"10.1021\/jacs.9b07578","article-title":"Versatile Peptide Macrocyclization with Diels\u2013Alder Cycloadditions","volume":"141","author":"Montgomery","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e202311186","DOI":"10.1002\/anie.202311186","article-title":"Merging the Isonitrile-Tetrazine (4+1) Cycloaddition and the Ugi Four-Component Reaction into a Single Multicomponent Process","volume":"62","author":"Vasco","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","article-title":"Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized \u03b1-Helical Peptide in Clinical Development","volume":"66","author":"Guerlavais","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"17942","DOI":"10.1073\/pnas.1208396109","article-title":"Inhibition of oncogenic Wnt signaling through direct targeting of \u03b2-catenin","volume":"109","author":"Grossmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41421-020-0171-1","article-title":"A PROTAC peptide induces durable \u03b2-catenin degradation and suppresses Wnt-dependent intestinal cancer","volume":"6","author":"Liao","year":"2020","journal-title":"Cell Discov."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/0008-5472.CAN-15-1680","article-title":"Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion","volume":"76","author":"Teng","year":"2016","journal-title":"Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"E5669","DOI":"10.1073\/pnas.1721173115","article-title":"Targeting the potent Beclin 1-UVRAG coiled-coil interaction with designed peptides enhances autophagy and endolysosomal trafficking","volume":"115","author":"Wu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1021\/acs.jmedchem.1c00870","article-title":"Optimization of Beclin 1-Targeting Stapled Peptides by Staple Scanning Leads to Enhanced Antiproliferative Potency in Cancer Cells","volume":"64","author":"Yang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/bmc-2015-0035","article-title":"Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches","volume":"7","author":"Feng","year":"2016","journal-title":"Biomol. Concepts"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41570-023-00493-y","article-title":"Synthesis and applications of mirror-image proteins","volume":"7","author":"Harrison","year":"2023","journal-title":"Nat. Rev. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/tcr.201600005","article-title":"D-Peptides as Recognition Molecules and Therapeutic Agents","volume":"16","author":"Liu","year":"2016","journal-title":"Chem. Rec."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1021\/la804271d","article-title":"Supramolecular hydrogel of a D-amino acid dipeptide for controlled drug release in vivo","volume":"25","author":"Liang","year":"2009","journal-title":"Langmuir"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e3066","DOI":"10.1002\/psc.3066","article-title":"Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3","volume":"24","author":"Pallerla","year":"2018","journal-title":"J. Pept. Sci."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Chen, X., Fan, Z., and Chen, Y. (2013). Retro-inverso carbohydrate mimetic peptides with annexin1-binding selectivity, are stable in vivo, and target tumor vasculature. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080390"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1021\/jm3005465","article-title":"An ultrahigh affinity d-peptide antagonist Of MDM2","volume":"55","author":"Zhan","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Lander, A.J., Jin, Y., and Luk, L.Y.P. (2023). D-Peptide and D-Protein Technology: Recent Advances, Challenges, and Opportunities. ChemBioChem, 24.","DOI":"10.1002\/cbic.202200537"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"19572","DOI":"10.1074\/jbc.M110.116814","article-title":"Limitations of peptide retro-inverso isomerization in molecular mimicry","volume":"285","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1016\/j.bmc.2013.04.039","article-title":"Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53\u2013MDM2 interaction","volume":"21","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of d-Peptide Ligands Through Mirror-Image Phage Display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-peptide inhibitors of the p53\u2013MDM2 interaction for targeted molecular therapy of malignant neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"15114","DOI":"10.1002\/anie.202002783","article-title":"A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT\/PVR for Cancer Immunotherapy","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/acschembio.5b01006","article-title":"A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo","volume":"11","author":"Uppalapati","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/anie.201000329","article-title":"A left-handed solution to peptide inhibition of the p53-MDM2 interaction","volume":"49","author":"Liu","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"14779","DOI":"10.1073\/pnas.1210483109","article-title":"Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography","volume":"109","author":"Mandal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ccell.2017.02.017","article-title":"Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer","volume":"31","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1021\/jacs.1c12075","article-title":"Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer","volume":"144","author":"Zhou","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2002197","DOI":"10.1002\/adhm.202002197","article-title":"An NRP1\/MDM2-Targeted D-Peptide Supramolecular Nanomedicine for High-Efficacy and Low-Toxic Liver Cancer Therapy","volume":"10","author":"Zhou","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41467-017-02618-6","article-title":"Peptidomimetic blockade of MYB in acute myeloid leukemia","volume":"9","author":"Ramaswamy","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1021\/jm5010896","article-title":"Peptides Containing \u03b2-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry","volume":"57","author":"Cabrele","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1517\/17460441.2011.632002","article-title":"Peptide and peptoid foldamers in medicinal chemistry","volume":"6","author":"Horne","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/cbdv.200790121","article-title":"ADME Investigations of Unnatural Peptides: Distribution of a 14C-Labeled \u03b2\u20093-Octaarginine in Rats","volume":"4","author":"Weiss","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cbdv.200490087","article-title":"The world of beta- and gamma-peptides comprised of homologated proteinogenic amino acids and other components","volume":"1","author":"Seebach","year":"2004","journal-title":"Chem. Biodivers."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/ar960298r","article-title":"Foldamers: A manifesto","volume":"31","author":"Gellman","year":"1998","journal-title":"Acc. Chem. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1039\/C1CS15097A","article-title":"Peptidic foldamers: Ramping up diversity","volume":"41","author":"Martinek","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1039\/b501173f","article-title":"Application of alicyclic \u03b2-amino acids in peptide chemistry","volume":"35","author":"Martinek","year":"2006","journal-title":"Chem. Soc. Rev."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1021\/ja910715u","article-title":"Bridged beta(3)-peptide inhibitors of p53-hDM2 complexation: Correlation between affinity and cell permeability","volume":"132","author":"Bautista","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.bmc.2009.01.039","article-title":"\u03b2-Peptides with improved affinity for hDM2 and hDMX","volume":"17","author":"Harker","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1021\/acschembio.5b00109","article-title":"Residue-Based Preorganization of BH3-Derived \u03b1\/\u03b2-Peptides: Modulating Affinity, Selectivity and Proteolytic Susceptibility in \u03b1-Helix Mimics","volume":"10","author":"Haase","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1021\/ja302469a","article-title":"Extending Foldamer Design beyond \u03b1-Helix Mimicry: \u03b1\/\u03b2-Peptide Inhibitors of Vascular Endothelial Growth Factor Signaling","volume":"134","author":"Haase","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Connolly, M.D., Xuan, S., and Molchanova, N. (2021). Chapter Eight\u2014Submonomer synthesis of sequence defined peptoids with diverse side-chains. Methods in Enzymology, Academic Press.","DOI":"10.1016\/bs.mie.2021.04.022"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Zhu, J., Chen, S., and Liu, Z. (2023). Recent advances in anticancer peptoids. Bioorg. Chem., 139.","DOI":"10.1016\/j.bioorg.2023.106686"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1039\/c2sm07092h","article-title":"Determination of the persistence length of helical and non-helical polypeptoids in solution","volume":"8","author":"Rosales","year":"2012","journal-title":"Soft Matter"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Huang, W., Seo, J., and Willingham, S.B. (2014). Learning from host-defense peptides: Cationic, amphipathic peptoids with potent anticancer activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090397"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acspolymersau.2c00036","article-title":"A Field Guide to Optimizing Peptoid Synthesis","volume":"2","author":"Clapperton","year":"2022","journal-title":"ACS Polym. Au"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/ajoc.202100264","article-title":"Solid-Phase Synthesis of Peptidomimetics with Peptide Backbone Modifications","volume":"10","author":"Abdildinova","year":"2021","journal-title":"Asian J. Org. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Brekker, M.A., Sartawi, T., and Sawatzky, T.M. (2022). A peptoid-based inhibitor of protein arginine methyltransferase 1 (PRMT1) induces apoptosis and autophagy in cancer cells. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.102205"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1038\/s41467-018-06845-3","article-title":"Design of Peptoid-peptide Macrocycles to Inhibit the \u03b2-catenin TCF Interaction in Prostate Cancer","volume":"9","author":"Schneider","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Zhang, H., and Udugamasooriya, D.G. (2022). Optimization of a cell surface vimentin binding peptoid to extract antagonist effect on lung cancer cells. Bioorg. Chem., 129.","DOI":"10.1016\/j.bioorg.2022.106113"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3117\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:04:04Z","timestamp":1760029444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":217,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26073117"],"URL":"https:\/\/doi.org\/10.3390\/ijms26073117","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}